1

# Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors

Yong-Moon Mark Park, MD, PhD<sup>1,2\*</sup>, Wonyoung Jung, MD<sup>3,4\*</sup>, Yohwan Yeo, MD<sup>5</sup>, Sang Hyun Park, PhD<sup>6</sup>, Michael G. Fradley, MD<sup>7</sup>, Sindhu J. Malapati, MD<sup>2,8</sup>, Tushar Tarun, MD<sup>9</sup>, Vinay Raj, PhD<sup>10</sup>, Hong Seok Lee, MD, MPH<sup>11</sup>, Tasneem Z. Naqvi, MD, MMM<sup>12</sup>, Ronda S. Henry-Tillman, MD<sup>2,13</sup>, Jawahar L. Mehta, MD<sup>9</sup>, Mario Schootman, PhD<sup>2,14</sup>, Benjamin C. Amick III, PhD<sup>1,2</sup>, Kyungdo Han, PhD<sup>15\*\*</sup>, Dong Wook Shin, MD, MBA, DrPH<sup>16,17\*\*</sup>

<sup>1</sup> Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR

<sup>2</sup> Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR

<sup>3</sup> Department of Family Medicine, College of Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea

<sup>4</sup> Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

<sup>5</sup> Department of Family Medicine, College of Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea

<sup>6</sup> Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

<sup>7</sup> Cardio-Oncology Program, Division of Cardiology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA

<sup>8</sup> Division of Medical Oncology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR

<sup>9</sup>Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences Little Rock, AR

<sup>10</sup> Department of Biology & Department of Math and Computer Science, University of Arkansas at Pine Bluff, AR

<sup>11</sup> Division of Cardiology, Sarver Heart Center, Banner University Medical Group, University of Arizona, Tucson, AZ

<sup>12</sup> Division of Echocardiography, Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona

<sup>13</sup> Division of Breast Surgical Oncology, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR

<sup>14</sup> Department of Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR

<sup>15</sup> Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea

<sup>16</sup> Department of Family Medicine and Supportive Care Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

<sup>17</sup> Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea

2

<sup>\*</sup>These authors contributed equally.

\*\*Corresponding Authors:

Dong Wook Shin, MD, MBA, DrPH

Department of Family Medicine and Supportive Care Center, Samsung Medical Center, 81 Irwon-Ro, Gangnam-gu, Seoul 06351, Republic of Korea.

Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Republic of Korea

E-mail: dwshin.md@gmail.com

Kyungdo Han, PhD Department of Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul, 06978, Republic of Korea. E-mail: hkd917@naver.com Tel: +82-2-820-7025 ORCID ID: 0000-0002-6096-1263

Word count: 3,255

Running Title: AF risk among breast cancer surgery survivors

Conflict of Interest Disclosures: None reported.

**Data Availability Statement:** The data will be made available upon request and approval of a proposal by the National Health Insurance Service Database.

**Funding Statement:** This research was partly supported by a grant from the Arkansas Breast Cancer Research Program.

**Ethics Approval and Consent to Participate**: This study was approved by the Samsung Medical Center (Seoul, South Korea; SMC 2020-03-108) Institutional Review Board. All information used for analyses was anonymized and de-identified; therefore, informed consent was not required.

Consent for publication: Not applicable

Acknowledgement: None

#### 3

#### Abstract

**Background:** The mid- and long-term risk of incident atrial fibrillation (AF) among breast cancer survivors, especially for younger women, and cancer treatment effects on the association remain unclear. We aimed to investigate the risk of AF among breast cancer survivors and evaluate the association by age group, length of follow-up, and cancer treatment.

**Methods:** Using data from the Korean Health Insurance Service database between January 2010 and December 2017, 113,232 women newly diagnosed with breast cancer (aged  $\geq$ 18 years) without prior AF history who underwent breast cancer surgery were individually matched 1:5 by birth year to a sample female population without cancer (n=566,160). Subdistribution hazard ratios (sHRs) and 95% confidence intervals (CIs) considering death as a competing risk were estimated, adjusting for sociodemographic factors and cardiovascular/non-cardiovascular comorbidities.

**Results:** During follow-up (mean [SD] follow-up, 5.1 [2.1] years), AF developed in 1,166 (1.0%) breast cancer surgery survivors at least 1 year after enrollment. Overall, breast cancer survivors had a slightly increased AF risk compared to their cancer-free counterparts (sHR 1.06; 95% CI 1.00-1.13), but the association disappeared over time. Younger breast cancer survivors (age<40 years) had more than a 2-fold increase in AF risk (sHR 2.79; 95% CI 1.98-3.94), with the association remaining similar over 5 years of follow-up. The increased risk was not observed among older breast cancer survivors, especially those aged>65 years. Breast cancer survivors who received anthracyclines had an increased risk of AF compared to those without the exposure (sHR 1.57; 95% CI 1.28-1.92) over the entire course of follow-up. The association between anthracyclines and AF incidence was also more robust in younger breast cancer survivors (sHR 1.94; 95% CI 1.40-2.69 in those aged  $\leq$ 50 years). Sensitivity analyses, including further adjustments for obesity and lifestyle factors, supported the results.

**Conclusions:** Our findings suggest that younger breast cancer survivors had an elevated risk of incident AF, regardless of the length of follow-up. The use of anthracyclines may increase the mid-to-long-term AF risk among breast cancer surgery survivors.

Key Words: Atrial fibrillation, breast cancer, anthracyclines, younger breast cancer survivors

#### BACKGROUND

Individuals treated for breast cancer may be at increased risk of developing atrial fibrillation (AF), which is one of the key drivers of cardiovascular (CV) complications such as myocardial ischemia, stroke, and heart failure.[1, 2] Proposed mechanisms for increased risk of AF among breast cancer survivors include shared common risk factors such as advancing age, alcohol consumption, smoking, and obesity, as well as cancer-related proinflammatory state and cardiotoxic cancer treatment.[1-3] Due to increased early detection and improved survival following breast cancer treatment,[4] mid- to long-term CV complications have become a major concern of breast cancer survivors.[2]

The evidence regarding the risk of AF among breast cancer survivors has been primarily derived from studies limited by relatively small numbers of patients evaluated over a short period.[5] Additionally, most studies have focused on women over 65 years,[6, 7] or have been limited by the short-term follow-up (e.g., <3 years),[6, 8] small numbers of incident AF events,[9] use of prevalent breast cancer cases,[8, 10] early-stage breast cancer,[11] and failure to consider competing risks (e.g., death)[8, 12, 13] and comprehensive cancer treatment effects.[12-14] Consequently, the risk of AF among breast cancer survivors is unknown.

Breast cancer and CV events in women vary with age, particularly before and after menopause onset.[2] For instance, compared to those without cancer, women aged <40 years with breast cancer are at more than a 3-fold increased risk of developing CV complications,[15] and women diagnosed with breast cancer before age 50 years are at a higher risk of developing treatment-related CV complications.[16] However, few studies have investigated whether AF risk differs between younger and older breast cancer survivors,[8] particularly in Asian women, whose breast cancer incidence peaks in the mid to late 40s, which is remarkably different from that observed in Western countries.[17] Using the Korean

5

National Health Insurance Service (NHIS) database, we evaluated incident AF among breast cancer survivors compared with women without cancer, particularly investigating the mid- to long-term risk of AF and the impact of cancer treatment on this association by the age at the time of breast cancer diagnosis.

#### METHODS

#### **Data Source and Study Setting**

The NHIS is a public health insurance program providing mandatory universal coverage to 97% of the South Korean population. The NHIS database comprises sociodemographic and claims-based healthcare information such as medical procedures, diagnoses, prescriptions, outpatient visits, and hospital admission.[18, 19] The NHIS also operates biennial standardized health screening examinations,[20] which include past medical history, lifestyle behaviors (smoking, drinking, and physical activity), anthropometric measurements, and laboratory tests for nonemployees aged ≥40 years and employees regardless of age. The NHIS database has been validated for epidemiological and clinical research.[21, 22]

This study was approved by the Samsung Medical Center (Seoul, South Korea; SMC 2020-03-108) Institutional Review Board. All information used for analyses was anonymized and de-identified; therefore, informed consent was not required. The database is open to all researchers whose study protocols are approved by the official review committee.

#### **Study Population**

We identified 129,548 women newly diagnosed with invasive breast cancer who had undergone breast cancer surgery between January 1, 2010, and December 31, 2017, based on both International Classification of Diseases, Tenth Revision (ICD-10) codes (C50) and cancer-specific insurance claim code (V193 code). This V code was used to ensure the accuracy of breast cancer diagnosis because it is a reimbursement code representing biopsy-

6

confirmed cancers in South Korea.[23] We excluded those who did not undergo breast cancer surgery to avoid late-stage or aggressive breast cancer cases. Additionally, we excluded those who had a history of any cancer (n=12,043), were younger than 18 years old (n=17), or had a prior history of AF (n=2,148). We further excluded person-time within the first year of follow-up to reduce the bias related to undetected AF present at baseline and the acute effect of breast cancer treatments on AF risk[1] (n=2,108). The resulting 113,232 breast cancer survivors were matched 1:5 to women with no history of cancer or AF (n=566,160) from the general population based on birth year at baseline. Data recorded through December 31, 2020, were included in our analyses (**Figure 1**).

#### Measurements

The primary outcome was incident AF, based on ICD-10 codes I48.0–I48.4, and I48.9. AF diagnosis using ICD-10 codes in the NHIS has been shown to be 94.1% accurate.[24] We defined individuals with AF as those who had a discharge diagnosis or visited an outpatient clinic more than twice to exclude those with transient AF and improve diagnostic accuracy.[25]

Breast cancer treatment information was based on the claims data within 1 year after the breast cancer diagnosis.[23, 26] Chemotherapy was defined as at least 1 treatment cycle of a chemotherapeutic agent (anthracyclines [epirubicin or doxorubicin], cyclophosphamide, and taxane-based regimens [docetaxel or paclitaxel]). Due to the reimbursement policy in the NHIS, most patients administered taxane-based regimens tended to take anthracyclines in the adjuvant setting, indicating that those given taxanes could also be included in a category of those who took anthracyclines.[26] Targeted therapy was defined as at least one treatment cycle of Herceptin (trastuzumab). Endocrine therapy was defined as treatment with tamoxifen or aromatase inhibitors (anastrozole, exemestane, and letrozole), categorizing the use of a specific regimen based on the initial prescription when there was a subsequent switching

7

between medicines. Radiation therapy was defined as at least one local or regional treatment.

Comorbid medical conditions were assessed using past medical history data and clinical and pharmacy ICD-10 codes. Comorbidities included hypertension, type 2 diabetes, dyslipidemia, coronary heart disease (CHD), congestive heart failure, stroke, chronic kidney disease, and chronic obstructive pulmonary disease (COPD). Comorbidities of participants were identified based on laboratory measures, claims, and prescription information prior to the index date as follows: hypertension (ICD-10 codes [I10.x-I13.x and I15.x], or being on antihypertensive medication or having blood pressure  $\geq$  140/90 mmHg), diabetes mellitus (DM) (ICD-10 codes [E11.x-E14.x] with antidiabetic medications, or a fasting glucose level  $\geq$  126 mg/dL), dyslipidemia (ICD-10 code E78.x with lipid-lowering medication, or total cholesterol level  $\geq$  240 mg/dL), coronary heart disease (ICD-10 codes [I21.x-I22.x] during hospitalization), congestive heart failure (ICD codes [150.x] for the first hospitalization), stroke (ICD-10 codes [I63.x-I64.x] during hospitalization, with claims for brain magnetic resonance imaging or brain computed tomography), chronic kidney disease (the glomerular filtration rate of <60mL/min/1.73 m2 as estimated by the Modification of Diet in Renal Disease equation), and chronic obstructive pulmonary disease (ICD-10 codes [J43.x-J44.x]). ICD-10 codes were also applied if recorded in at least two outpatient visits for coronary heart disease and stroke. In addition, the Charlson Comorbidity Index (CCI) was calculated based on ICD-10 codes. Income level was based on monthly health insurance premiums. Lowincome status was defined as being in the lowest quartile of monthly health insurance premiums or being enrolled in the Medical Aid program. The geographic area of residence was dichotomized by rural and urban areas using the primary local authority districts (shi/gun/gu).

#### **Statistical Analysis**

The baseline characteristics are presented as means with standard deviations or

8

numbers with percentages. Participant data were collected until the date of AF diagnosis, death, or end of the study, whichever occurred first. Person-time was calculated starting at 1 year after baseline. The crude AF incidence rate was assessed by dividing the number of events by the total number of person-years of follow-up presented as per 1,000 person-years. Competing risk survival statistics considering death as a competing risk were used to calculate the cumulative incidence of AF.[27] The AF incidence between women with and without breast cancer was compared using the Gray-K test.[28]

The Fine-Gray proportional sub-distribution hazards model was used to estimate subdistribution hazard ratios (sHRs) and 95% confidence intervals (CIs) for AF incidence with death as a competing risk.[29] The proportional hazards assumption was assessed using Schoenfeld's residuals, and no specific departure was observed. In addition to a crude model (Model 1), potential confounders were identified a priori based on a literature review; these included age at baseline (continuous variable), household income, and residential location, which were incorporated into Model 2 to account for sociodemographic characteristics. Model 3 further adjusted for the presence or absence of hypertension, type 2 diabetes, dyslipidemia, CHD, congestive heart failure, stroke, chronic kidney disease, and COPD to account for comorbidities. To examine AF risk by cancer treatment modalities among breast cancer survivors, we further adjusted for the use of anthracyclines, taxanes, trastuzumab, endocrine treatment, and radiation treatment in Model 4. All analyses were stratified by age categories (18–39, 40–50, 51–65, or  $\geq$ 66 years). Landmark analyses were performed using 2 landmark points (3 and 5 years after breast cancer diagnosis) to estimate AF risk in an unbiased way in individuals who were event-free at the landmark time and examine the longterm effects of breast cancer and its treatments on AF incidence.[30]

As a sensitivity analysis, we included person-time within the first year of follow-up to capture any short-term CV consequences. In addition, using a subset of data comprising

9

participants in the general health screening examination, we conducted sensitivity analyses among 72,560 women with and 292,468 without breast cancer to account for body mass index, smoking, alcohol consumption, and physical activity (see **Supplemental Methods** for measurement details). A potential effect modification by income status, residential location, and other comorbidities was evaluated through stratified analysis and interaction testing using a likelihood ratio test. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). The P values provided are two-sided, with the level of significance at 0.05.

#### RESULTS

#### **Baseline characteristics**

Baseline characteristics are shown in **Table 1**, stratified by the presence or absence of breast cancer. The mean study population age was 51.6 years, and 10.8% of participants were less than 40 years old. Individuals surgically treated for breast cancer (hereafter referred to as breast cancer survivors) were more likely to have hypertension, type 2 diabetes, dyslipidemia, CHD, congestive heart failure, chronic kidney disease, and COPD than women without cancer. Among breast cancer survivors, the proportions of use in each treatment option were 61.0% for chemotherapy, 15.0% for target therapy, 61.8% for endocrine treatment, and 69.8% for radiation therapy. Breast cancer survivors were less likely to have low incomes or live in rural areas. Overall, the prevalence of CV risk factors and comorbidities was higher in breast cancer survivors than in women without cancer in each age group (**Supplemental Table 1**).

#### Risk of AF in breast cancer survivors compared to the general population by age group

Risks of AF by age group are shown in **Figure 2** and **Table 2**. A total of 1,166 (1.0%) incident AF cases were identified at least 1 year after baseline during a mean (SD) of 5.1 (2.1) years of follow-up in breast cancer survivors. AF risk was 6% higher in breast cancer

10

survivors than those without cancer (Model 3: sHR 1.06, 95% CI 1.00-1.13) after adjusting for potential confounders. Associations differed by age group (*P* for interaction <0.001). Younger women (18–39 years) with breast cancer exhibited a 2.79-fold increased AF risk (sHR 2.79, 95% CI 1.98-3.94), whereas older women ( $\geq$ 66 years) with breast cancer exhibited a decreased AF risk (sHR 0.90, 95% CI 0.81-0.99), compared with those without cancer. In the landmark analyses, AF risk was attenuated over time, and there was no overall association with AF over 5 years after breast cancer diagnosis. However, younger women with breast cancer exhibited a sustained 2-fold increased risk in those aged <40 years and at least a 30% increased AF risk in those aged ≤50 years during follow-up (**Supplemental Table 2**). In contrast, the inverse association tended to persist in those aged >65 years (*P* for interaction for age group in both landmark analyses <0.05).

#### **Risk of AF by treatment modalities**

Risks of AF by cancer treatment modalities among breast cancer survivors are shown in **Table 3**. Individuals who received anthracyclines had a 57% higher AF risk compared with those who did not (Model 4: sHR 1.57, 95% CI 1.28-1.92), whereas tamoxifen users had a 19% lower AF risk compared with those who did not receive endocrine treatment (sHR 0.81, 95% CI 0.70-0.95). Taxane-based chemotherapy was associated with increased AF risk (Model 3: sHR 1.20, 95% CI 1.06-1.35), but the association became nonsignificant after further adjusting for other cancer treatment modalities (Model 4: sHR 0.84, 95% CI 0.69-1.02). Other cancer therapies, including trastuzumab, aromatase inhibitors, and radiation treatment, were not associated with AF incidence. In the landmark analyses, the use of anthracyclines showed persistent increased AF risk over the follow-up period. In contrast, the inverse association between tamoxifen use and AF risk tended to disappear.

Risks of AF according to cancer treatment modalities and age group among breast cancer survivors are shown in **Table 4**. The use of anthracyclines was associated with

11

increased AF risk in all age groups, with a stronger association among younger women aged  $\leq$ 50 years. The inverse association between tamoxifen use and AF risk also tended to be clearer among younger women aged  $\leq$ 50 years (**Supplemental Table 3**). In the landmark analyses, the use of anthracyclines tended to be consistently associated with increased AF risk in each age group over the follow-up. In contrast, the inverse association between tamoxifen use and AF risk was no longer significant (**Supplemental Table 4**).

#### Stratified and sensitivity analyses

In stratified analyses, increased AF risk was observed only for those without CHD (*P* for interaction=0.04) or those without COPD (*P* for interaction=0.06) among women with breast cancer of all ages (**Supplemental Table 5**). When we included person-time within the first year of follow-up, the associations tended to be stronger, particularly in younger breast cancer survivors (aged  $\leq$ 50 years) (**Supplemental Table 6**). In contrast, meaningful changes were not observed in risks of AF by cancer treatment modalities among breast cancer survivors (**Supplemental Table 7**). The results were not materially changed in analyses limited to participants in the NHIS health examinations where body mass index, smoking, alcohol consumption, and physical activity were further adjusted for (**Supplemental Tables 8** & 9).

12

#### DISCUSSION

In this nationwide population-based cohort study, younger breast cancer survivors had increased AF risk compared to an age-matched sample of females with no cancer history from the general population; the strength of this association remained persistent over 5 years of follow-up. Breast cancer survivors aged <40 years had a more than 2-fold increased AF risk during the follow-up; this elevated risk was not observed in older breast cancer survivors, particularly those aged >65 years. Among breast cancer survivors, those treated with anthracyclines had a more pronounced AF risk than those not exposed to this chemotherapeutic. The association was strongest in breast cancer survivors aged ≤50 years and remained persistent over the follow-up period.

Newly developed AF in individuals with cancer may have an adverse effect on prognosis. In a study using the US Surveillance, Epidemiology, and End Results Medicare registry data, older women aged >65 years with breast cancer who developed incident AF within the first 30 days of breast cancer diagnosis were 3 times more likely to die of a CV condition within 1 year compared with those without incident AF.[6] In a Taiwanese retrospective cohort study, individuals with cancer who developed new-onset AF had an increased risk of thromboembolism and heart failure, although all-cause mortality was not elevated.[31] In contrast, new-onset AF in those with lymphoma was positively associated with both acute heart failure and all-cause mortality.[32] In addition, there was a higher risk of bleeding in patients with cancer and AF than in those without AF.[33]

While we initially observed an overall positive association between breast cancer and the risk of developing AF, it was marginal and became null over the follow-up period. These results are similar to previous studies, which were unable to show a strong association between breast cancer and incident AF compared to other types of cancer.[13, 14] The strength of the association with the risk of incident AF also decreased over time, with the

13

highest risk occurring in the first year of diagnosis,[6, 7, 11, 13, 14] which was also observed in our study. This transient, increased risk of developing AF shortly after breast cancer diagnosis might be due to surgical and/or medical cancer therapy, autonomic nervous system imbalance, pre-existing chronic inflammatory state, cancer-related comorbidities, or the combination of these conditions.[1] To assess the mid- to long-term risk of AF among breast cancer survivors, we excluded AF incidence in the first year of follow-up to mitigate the effects of these potential confounding factors.

In our study, younger survivors, particularly those <40 years, showed a stronger association with incident AF than older breast cancer survivors. The increased risk remained persistent over 5 years of the follow-up after adjusting for cardiometabolic comorbidities. A previous study reported that breast cancer survivors <60 years had a stronger association with incident AF than older breast cancer survivors.[8] It is unclear why the association differs by age group. In our stratified analyses, among those without CV risk factors or CVD at baseline, breast cancer survivors had a higher AF risk compared to the general population. This suggests that AF incidence between older breast cancer survivors and the general population might not be different due to the increased prevalence of CV risk factors and comorbid CVD as women age. However, the prevalence of CV risk factors and comorbidities in women aged >50 years was still higher in breast cancer survivors compared to the general population in our study. The other speculation is that younger patients receive more intensive, cardiotoxic treatments than older patients.[8] As such, regular cardiac surveillance or monitoring for AF may be warranted, although further research is needed to establish a specific prevention strategy.[34]

We observed a positive association between the use of anthracyclines and subsequent increased AF risk after accounting for the use of other cancer treatment modalities. After adjusting for other cancer treatment modalities, there was no significant association between

14

the use of taxanes and AF occurrence, suggesting that the observed unadjusted association was likely driven by the concomitant use of anthracyclines.[26] This is consistent with prior findings from a recent study of the World Health Organization dataset VigiBase of more than 130 countries, which reported that those who developed AF were more likely to use anthracyclines, adjusting for the use of other anticancer medications.[35] In contrast, our findings differ from those of previous studies from the US[6] and Canada,[11] where anthracycline use was not associated with increased AF risk, possibly because of different study population characteristics such as racial/ethnic differences.[36] However, racial/ethnic difference in cardiotoxicity is understudied and further studies are warranted to confirm the observed finding.[37] An inverse association between tamoxifen use and AF risk among younger breast cancer survivors aged  $\leq$ 50 years tended to diminish gradually with increasing follow-up duration. This finding suggests that the benefit of tamoxifen use may be limited to reduced risk of early CV outcomes in breast cancer survivors.[38]

Given the limitations of claims data, we cannot provide clinical details, including cancer stage, cardiac imaging, pathological results, surgery types, and chemotherapy dosage. In addition, misclassification and unmeasured confounding may exist as a result of limitations inherent to claims data. However, we investigated the mid- to long-term risk of AF after a breast cancer diagnosis and its surgical/medical treatments using data from a large sample size of 113,232 women newly diagnosed with breast cancer. While other non–cancer-related factors may have contributed to the development of AF, we did perform various sensitivity analyses, including further adjustment for obesity and lifestyle characteristics to minimize bias.

#### CONCLUSIONS

In conclusion, young breast cancer surgery survivors, specifically those aged <40

years and those treated with anthracyclines, may be at a higher mid- to long-term risk of AF.

Our findings underscore the need for increased awareness of AF risk in this population.

### LIST OF ABBREVIATIONS

- AF, atrial fibrillation
- CHD, coronary heart disease
- CI, confidence interval
- COPD, chronic obstructive pulmonary disease
- CV, cardiovascular
- DM, diabetes mellitus
- NHIS, National Health Insurance Service
- SD, standard deviation
- sHR, sub-distribution hazard ratio

## REFERENCES

1. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945-53.

2. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137(8):e30-e66.

3. Merino JL. Atrial fibrillation and breast cancer: casual or causal relationship? Eur Heart J. 2022;43(4):313-5.

4. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-85.

5. Mauro E, Lucà F, Tetta C, Parise O, Parrini I, Parise G, et al. Breast Cancer and Atrial Fibrillation. J Clin Med. 2022;11(5).

6. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J. 2022;43(4):300-12.

7. Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Bhaskaran K, et al. Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study. J Natl Compr Canc Netw. 2021:1-10.

8. D'Souza M, Smedegaard L, Madelaire C, Nielsen D, Torp-Pedersen C, Gislason G, et al. Incidence of atrial fibrillation in conjunction with breast cancer. Heart Rhythm. 2019;16(3):343-8.

9. Conen D, Wong JA, Sandhu RK, Cook NR, Lee IM, Buring JE, et al. Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. JAMA Cardiol. 2016;1(4):389-96.

10. O'Neal WT, Lakoski SG, Qureshi W, Judd SE, Howard G, Howard VJ, et al. Relation Between Cancer and Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). The American Journal of Cardiology. 2015;115(8):1090-4.

11. Abdel-Qadir H, Thavendiranathan P, Fung K, Amir E, Austin PC, Anderson GS, et al. Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation. JAMA Netw Open. 2019;2(9):e1911838.

12. Saliba W, Rennert HS, Gronich N, Gruber SB, Rennert G. Association of atrial fibrillation and cancer: Analysis from two large population-based case-control studies. PLoS One. 2018;13(1):e0190324.

13. Jakobsen CB, Lamberts M, Carlson N, Lock-Hansen M, Torp-Pedersen C, Gislason GH, et al. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 gear follow up study. BMC Cancer. 2019;19(1):1105.

14. Yun JP, Choi EK, Han KD, Park SH, Jung JH, Park SH, et al. Risk of Atrial Fibrillation According to Cancer Type: A Nationwide Population-Based Study. JACC CardioOncol. 2021;3(2):221-32.

15. Chao C, Xu L, Bhatia S, Cooper R, Brar S, Wong FL, et al. Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. J Clin Oncol. 2016;34(14):1626-33.

16. Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, et al. Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors. Int J Radiat Oncol Biol Phys. 2016;94(5):1061-72.

17. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308-24.

18. Lee YH, Han K, Ko SH, Ko KS, Lee KU. Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by

National Health Insurance Service. Diabetes Metab J. 2016;40(1):79-82.

19. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46(3):799-800.

20. Shin DW, Cho J, Park JH, Cho B. National General Health Screening Program in Korea: history, current status, and future direction. Precis Future Med. 2022;6(1):9-31.

21. Seo HJ, Oh IH, Yoon SJ. A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2012;13(12):6163-8.

22. Lee CK, Ha HJ, Oh SJ, Kim JW, Lee JK, Kim HS, et al. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. J Gastroenterol Hepatol. 2020;35(5):760-8.

23. Chung IY, Lee J, Park S, Lee JW, Youn HJ, Hong JH, et al. Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data. J Korean Med Sci. 2018;33(44):e276.

24. Lee SS, Ae Kong K, Kim D, Lim Y-M, Yang P-S, Yi J-E, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. European Heart Journal. 2017;38(34):2599-607.

25. Choi EK. Cardiovascular Research Using the Korean National Health Information Database. Korean Circ J. 2020;50(9):754-72.

26. Lee J, Hur H, Lee JW, Youn HJ, Han K, Kim NW, et al. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group. Cancer. 2020;126(1):181-8.

27. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clinical cancer research. 2007;13(2):559-65.

28. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of statistics. 1988:1141-54.

29. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American statistical association. 1999;94(446):496-509.

30. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363-71.

31. Hu Y-f, Liu C-j, Chang PM-h, Tsao H-m, Lin Y-j, Chang S-l, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. International journal of cardiology. 2013;165(2):355-7.

32. Amioka M, Sairaku A, Ochi T, Okada T, Asaoku H, Kyo T, et al. Prognostic significance of new-onset atrial fibrillation in patients with non-Hodgkin's lymphoma treated with anthracyclines. The American Journal of Cardiology. 2016;118(9):1386-9.

33. Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017;3(3):192-7.

34. Madnick DL, Fradley MG. Atrial Fibrillation and Cancer Patients: Mechanisms and Management. Curr Cardiol Rep. 2022;24(10):1517-27.

35. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-20.

36. Zhang L, Song J, Clark R, Mangoni A, Goldberg Y, Slipczuk L, et al. Racial and Ethnic Differences in Anthracycline Cardiotoxicity. Circulation. 2021;144(Suppl\_1):A13090-A.

37. Prasad P, Branch M, Asemota D, Elsayed R, Addison D, Brown S-A. Cardio-

18

oncology preventive care: racial and ethnic disparities. Current Cardiovascular Risk Reports. 2020;14(10):1-14.

38. Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, et al. Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up. Breast Cancer Res Treat. 2013;138(2):467-73.

#### 19

#### FIGURE LEGENDS

#### Figure 1. Participant flow diagram

After excluding participants meeting exclusion criteria, 113,232 subjects were included in the final analysis.

#### Figure 2. Cumulative incidence of Atrial Fibrillation (AF) by age group

Cumulative incidence function plots for atrial fibrillation (AF) in breast cancer surgery survivors display that breast cancer surgery survivors had a consistently higher incidence of AF compared to their age-matched noncancer female general population in those aged 18-39 (Figure 2a, P<0.001), aged 40-50 (Figure 2b, P=0.003), and aged 51-65 (Figure 2c, P<0.001).

#### **Figure 3. Graphical Abstract**

The graphical abstract illustrates the objectives, methods, and findings of this study.

### Table 1 Baseline characteristics of the study population

	Breast Cancer					
	No	Yes				
	(N=566,160)	(N=113,232)				
Age at baseline, mean (SD), years	51.6 (10.8)	51.6 (10.8)				
Age group, years						
18-39	61,325 (10.8)	12,265 (10.8)				
40-50	202,435 (35.8)	40,487 (35.8)				
51-65	235,670 (41.6)	47,134 (41.6)				
≥66	66,730 (11.8)	13,346 (11.8)				
Comorbidity						
Hypertension	122,631 (21.7)	28,779 (25.4)				
Type 2 diabetes	39,756 (7.0)	10,027 (8.9)				
Dyslipidemia	100,734 (17.8)	23,068 (20.4)				
Coronary heart disease	33,511 (5.9)	8,732 (7.7)				
Congestive heart failure	7,670 (1.4)	3,046 (2.7)				
Stroke	12,177 (2.2)	2,464 (2.2)				
Chronic kidney disease	4,444 (0.8)	1,285 (1.1)				
Chronic obstructive pulmonary disease	53,517 (9.5)	20,698 (18.3)				
Charlson comorbidity index, mean (SD)	0.9 (1.2)	2.5 (1.3)				
Cancer treatment type						
Chemotherapy, Yes		69,056 (61.0)				
Anthracyclines		58,709 (85.0)				
Cyclophosphamide		65,140 (94.3)				
Fluorouracil		15,801 (22.9)				
Taxane		36,417 (52.7)				
Others <sup>*</sup>		7,937 (11.5)				
Trastuzumab, Yes		16,945 (15.0)				
Endocrine therapy, Yes		77,925 (61.8)				
Tamoxifen		49,574 (43.8)				
Aromatase inhibitors		27,046 (23.9)				
Both		1,305 (1.2)				
Radiation therapy, Yes		79,076 (69.8)				
Income status, Low	140,488 (24.8)	25,507 (22.5)				
Residential location, Urban	265,234 (46.8)	56,703 (50.1)				
Conservation and the second section of the second sector	No	Yes				
General health examination participants	(N=292,648)	(N=72,560)				
Smoking, Ever	14,835 (5.1)	4,216 (5.8)				
Alcohol consumption ( $\geq 10g$ ), Yes	70,695 (24.2)	17,531 (24.2)				
Regular physical activity <sup>**</sup> , Yes	54,062 (18.5)	13,330 (18.4)				
Body mass index, mean (SD), kg/m <sup>2</sup>	23.6 (3.3)	23.6 (3.4)				
Obesity (BMI $\geq 25$ kg/m <sup>2</sup> )	86,548 (29.6)	22,264 (30.7)				

Data are expressed as number (%) or mean (standard deviation) unless otherwise noted. \* Methotrexate or cisplatin.

<sup>\*\*</sup> Regular physical activity was defined as at least 30 minutes of moderate physical activity for  $\geq$ 5 days weekly or at least 20 minutes of strenuous physical activity  $\geq$ 2 days weekly

Age group		Subjects (N)	Case (n)	IR per 1,000 person-years	Model 1 (Crude) sHR (95% CI)	Model 2 sHR (95% CI)	Model 3 sHR (95% CI)	
Main	All ages	Noncancer	566,160	5,271	1.76	1(Ref.)	1(Ref.)	1(Ref.)
analysis Breast cancer		113,232	1,166	2.01	1.14 (1.07-1.22)	1.15 (1.08-1.23)	1.06 (1.00-1.13)	
•	18-39	Noncancer	61,325	91	0.27	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	12,265	51	0.78	2.94 (2.09-4.15)	2.95 (2.10-4.16)	2.79 (1.98-3.94)
	40-50	Noncancer	202,435	684	0.63	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	40,487	171	0.81	1.28 (1.09-1.52)	1.29 (1.09-1.53)	1.22 (1.03-1.45)
	51-65	Noncancer	235,670	2,123	1.71	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	47,134	497	2.06	1.21 (1.10-1.33)	1.22 (1.10-1.34)	1.13 (1.03-1.25)
	<u>≥66</u>	Noncancer	66,730	2,373	7.31	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	13,346	447	7.08	0.97 (0.88-1.07)	0.98 (0.89-1.09)	0.90 (0.81-0.99)
P for interac	tion					< 0.001	< 0.001	< 0.001
3-year	All ages	Noncancer	546,453	3,609	1.94	1(Ref.)	1(Ref.)	1(Ref.)
landmark	0	Breast cancer	107,153	777	2.17	1.12 (1.04-1.21)	1.13 (1.05-1.22)	1.05 (0.97-1.14)
analysis	18-39	Noncancer	59,817	60	0.28	1(Ref.)	1(Ref.)	1(Ref.)
•		Breast cancer	11,617	31	0.76	2.75 (1.78-4.24)	2.76 (1.79-4.26)	2.62 (1.70-4.05)
	40-50	Noncancer	196,863	472	0.69	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	38,727	117	0.89	1.28 (1.05-1.57)	1.29 (1.06-1.58)	1.23 (1.00-1.50)
	51-65	Noncancer	227,856	1,516	1.97	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	44,665	328	2.22	1.13 (1.00-1.27)	1.14 (1.01-1.28)	1.06 (0.94-1.20)
	<u>≥66</u>	Noncancer	61,917	1,561	8.04			1(Ref.)
		Breast cancer	12,144	301	8.06	1.00 (0.89-1.14)	1.02 (0.90-1.15)	0.93 (0.82-1.05)
P for interac	tion					< 0.001	< 0.001	< 0.001
5-year	All ages	Noncancer	546,453	1,918	2.11	1(Ref.)	1(Ref.)	1(Ref.)
landmark	0	Breast cancer	107,153	388	2.25	1.07 (0.96-1.19)	1.08 (0.96-1.19)	1.00 (0.90-1.12)
analysis	18-39	Noncancer	59,817	28	0.25	1(Ref.)	1(Ref.)	1(Ref.)
•		Breast cancer	11,617	12	0.59	2.32 (1.18-4.56)	2.33 (1.18-4.57)	2.22 (1.13-4.37)
	40-50	Noncancer	196,863	265	0.79	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	38,727	65	1.01	1.28 (0.98-1.68)	1.29 (0.98-1.69)	1.23 (0.94-1.62)
	51-65	Noncancer	227,856	812	2.18	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	44,665	163	2.31	1.06 (0.90-1.25)	1.06 (0.90-1.26)	1.00 (0.84-1.18)
	≥66	Noncancer	61,917	813	9.08	1(Ref.)	1(Ref.)	1(Ref.)
		Breast cancer	12,144	148	8.70	0.96 (0.80-1.14)	0.96 (0.81-1.15)	0.89 (0.74-1.06)
P for interac	tion					0.041	0.041	0.024

Table 2 Adjusted sub-distribution hazard ratios for developing atrial fibrillation in breast cancer surgery survivors compared to the noncancer general population by age categories

IR, incidence rate; PYs, person-years; sHR, sub-distribution hazard ratio; CI, confidence interval.

Model 2: adjusted for age, income status, and residential location.

Model 3: adjusted for Model 2 + hypertension, type 2 diabetes, dyslipidemia, coronary heart disease, congestive heart failure, chronic kidney disease, and chronic obstructive pulmonary disease.

					ID	Model 1 (Crude)	Model 2	Model 3	Model 4	
	Treatment type		Subjects (N)	Case (n)	IR per 1,000 PYs	sHR (95% CI)	sHR (95% CI)	sHR (95% CI)	sHR (95% CI)	
Main		No	54,523	591	2.14	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
analysis	Anthracyclines	Yes	58,709	575	1.89	0.88 (0.79-0.98)	1.39 (1.23-1.58)	1.39 (1.23-1.57)	1.57 (1.28-1.92)	
anaiysis		No	48,092	530	2.17	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
	Taxane	Yes	65,140	636	1.89	0.87 (0.77-0.97)	1.22 (1.08-1.37)	1.20 (1.06-1.35)	0.84 (0.69-1.02)	
		No	96,287	996	2.00	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
	Trastuzumab	Yes	16,945	170	2.00	1.03 (0.87-1.21)	1.15 (0.97-1.35)	1.11 (0.94-1.30)	0.96 (0.80-1.14)	
		No	35,307	386	2.19	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
		Tamoxifen	49,574	294	1.12	0.51 (0.44-0.59)	0.79 (0.68-0.92)	0.78 (0.67-0.92)	0.81 (0.70-0.95)	
	Endocrine therapy	AIs	27,046	471	3.46	1.58 (1.38-1.81)	1.01 (0.88-1.15)	1.00 (0.87-1.15)	1.00 (0.87-1.15)	
		Both	1,305	15	2.23	1.02 (0.61-1.70)	0.70 (0.42-1.17)	0.66 (0.40-1.11)	0.68 (0.41-1.14)	
		No	34,156	433	2.52	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
	Radiation therapy	Yes	79,076	733	1.79	0.71 (0.63-0.80)	1.01 (0.89-1.14)	1.02 (0.90-1.16)	0.98 (0.87-1.12)	
3-year		No	52,036	390	2.32	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
landmark	Anthracyclines	Yes	55,117	387	2.04	0.88 (0.76-1.01)	1.41 (1.22-1.64)	1.40 (1.21-1.63)	1.48 (1.16-1.90)	
analysis	Taxane	No	45,695	345	2.31	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
		Yes	61,458	432	2.07	0.90 (0.78-1.03)	1.27 (1.10-1.48)	1.25 (1.08-1.45)	0.91 (0.72-1.16)	
	Trastuzumab	No	91,190	663	2.15	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
		Yes	15,963	114	2.28	1.07 (0.88-1.30)	1.19 (0.98-1.46)	1.16(0.95-1.41)	0.99 (0.80-1.23)	
	Endocrine therapy	No	32,452	252	2.34	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
		Tamoxifen	47,839	208	1.27	0.54 (0.45-0.65)	0.85 (0.70-1.03)	0.85 (0.70-1.02)	0.89 (0.74-1.08)	
		AIs	25,633	308	3.72	1.59 (1.35-1.88)	0.99 (0.84-1.18)	0.99(0.83-1.17)	0.99 (0.83-1.17)	
		Both	1,229	9	2.16	0.92 (0.47-1.79)	0.62 (0.32-1.21)	0.59(0.30-1.14)	0.61 (0.31-1.18)	
	Radiation therapy	No	31,842	283	2.70	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
	Kaalallon inerapy	Yes	75,311	494	1.95	0.72 (0.62-0.84)	1.04 (0.89-1.21)	1.05 (0.90-1.22)	1.01 (0.87-1.18)	
5-year	Anthracyclines	No	34,664	183	2.32	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
landmark		Yes	39,965	205	2.20	0.95 (0.78-1.16)	1.57 (1.27-1.94)	1.56 (1.26-1.93)	1.56 (1.10-2.21)	
analysis	Taxane	No	31,154	160	2.28	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
		Yes	43,475	228	2.24	0.98 (0.80-1.20)	1.43 (1.16-1.76)	1.40 (1.14-1.73)	1.02 (0.72-1.43)	
	Trasturumah	No	64,089	332	2.22	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
-	Trastuzumab	Yes	10,540	56	2.45	1.11 (0.84-1.47)	1.24 (0.93-1.65)	1.20 (0.90-1.59)	1.01 (0.75-1.37)	
		No	22,325	115	2.23	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
	Endocrine therapy	Tamoxifen	34,191	116	1.46	0.65 (0.50-0.84)	1.04 (0.80-1.35)	1.04 (0.80-1.35)	1.13 (0.86-1.48)	
		AIs	17,253	152	3.89	1.74 (1.37-2.22)	1.07 (0.83-1.36)	1.06 (0.83-1.36)	1.08 (0.84-1.38)	
		Both	860	5	2.49	NA	NA	NA	NA	
	Radiation therapy	No	21,464	144	2.86	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)	
		Yes	53,165	244	2.00	0.70 (0.57-0.86)	1.02 (0.82-1.26)	1.03 (0.83-1.28)	0.98 (0.79-1.22)	

Table 3 Adjusted sub-distribution hazard ratios for developing atrial fibrillation by cancer treatment type among breast cancer surgery survivors

Model 2: adjusted for age, income status, and residential location.

Model 3: adjusted for Model 2 + hypertension, type 2 diabetes, dyslipidemia, coronary heart disease, congestive heart failure, chronic kidney disease, and chronic obstructive pulmonary disease.


Model 4: adjusted for Model 3 + use of anthracyclines, taxane, trastuzumab, endocrine therapy, and radiation therapy.

	Age 18-39			Age 40-50			Age 51-65			Age ≥66		
Treatment type	C/S	IR	sHR (95% CI)	C/S	IR	sHR (95% CI)	C/S	IR	sHR (95% CI)	C/S	IR	sHR (95% CI)
Anthracyclines												
No	9 /4,532	0.38	1 (Ref.)	59 /18,346	0.62	1 (Ref.)	195 /21,802	1.75	1 (Ref.)	328 /9,843	7.07	1 (Ref.)
Yes	42 /7,733	1.02	3.07 (1.47-6.42)	112 /22,141	0.95	1.69 (1.18-2.40)	302 /25,332	2.33	1.53 (1.20-1.93)	119 /3,503	7.10	1.51 (1.15-1.98)
Taxane			i			i						
No	15 /4,426	0.64	1 (Ref.)	56 /16,694	0.65	1 (Ref.)	170 /18,796	1.77	1 (Ref.)	289 /8,176	7.47	1 (Ref.)
Yes	36 /7,839	0.86	0.92 (0.49-1.71)	115 /23,793	0.92	0.93 (0.65-1.33)	327 /28,338	2.26	0.85 (0.67-1.09)	158 /5,170	6.45	0.81 (0.63-1.03)
Trastuzumab									, , ,			
No	44 /10,465	0.78	1 (Ref.)	142 /35,100	0.77	1 (Ref.)	410 /38,765	2.05	1 (Ref.)	400 /11,957	7.02	1 (Ref.)
Yes	7 /1,800	0.78	0.85 (0.38-1.89)	29 /5,387	1.08	1.16 (0.78-1.74)	87 /8,369	2.12	0.88 (0.69-1.12)	47 /1,389	7.57	1.05 (0.77-1.44)
Endocrine therapy			/							,		
No	24 /4,462	1.04	1 (Ref.)	53 /10,629	0.99	1 (Ref.)	168 /15,998	2.10	1 (Ref.)	141 /4,218	7.34	1 (Ref.)
Tamoxifen	27 /7,741	0.65	0.59 (0.34-1.02)	106 /28,566	0.70	0.72 (0.52-1.00)	91 /11,024	1.57	0.94 (0.72-1.21)	70 /2,243	6.32	0.82 (0.61-1.09)
AIs	0 /35	0	NA	8 /1,149	1.27	1.01 (0.48-2.13)	233 /19,253	2.37	1.04 (0.85-1.27)	230 /6,609	7.30	1.03 (0.84-1.27)
Both	0 /27	0	NA	4 /143	5.15	NA	5 /859	1.12	NA	6 /276	4.40	0.57 (0.25-1.28)
Radiation therapy												
No	12 /3,485	0.67	1 (Ref.)	42 /11,160	0.73	1 (Ref.)	144 /13,091	2.17	1 (Ref.)	235 /6,420	7.81	1 (Ref.)
Yes	39 /8,780	0.83	1.18 (0.62-2.25)	129 /29,327	0.83	1.11 (0.79-1.58)	353 /34,043	2.02	0.96 (0.79-1.17)	212 /6,926	6.41	0.99 (0.82-1.20)

 Table 4 Adjusted sub-distribution hazard ratios for developing atrial fibrillation by cancer treatment type among breast cancer surgery survivors by age categories


C/S, the number of cases/the number of subjects; IR, incidence rate (described as per 1,000 person-years); sHR, sub-distribution hazard ratio; CI, confidence interval; AIs, aromatase inhibitors; NA, Not applicable.

Hazard ratios were adjusted for age, income status, residential location, hypertension, type 2 diabetes, dyslipidemia, coronary heart disease, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, and history of anthracyclines, taxane, trastuzumab, endocrine therapy, and radiation therapy.



# Ages 18-39 years

# Ages 40-50 years



18.004

3,263

8.793

1,582

61,273 59.817 53.999 44.892 35.524 26,626 10,363

8,489


6,639

4,903

Ages 51-65 years

12,083

11,617



No. at risk

Women without cancer 61,325

Breast cancer survivors 12,265

Women without cancer 235,670 235,008 25,807 227.867 200.332 160.443 122.368 87.946 56.249 Breast cancer survivors 47,134 46,575 44,670 38,921 30,853 23,326 16,636 10,553 4,828

# Ages ≥ 66 years

175,582

34,306

141,884

27.537

109,848

21.131

79,528

15.143

51,718

9.801


24,642

4.647

196,864

38,728

40.112



#### Time from baseline (years)

No. at risk Women without cancer 66,730 65,478 Breast cancer survivors 13,346 12,967

Women without cancer 202,435 202,180

Breast cancer survivors 40,487

61.919 52.341 12,146 10,162

40.382 29.992 20.790 12.612 5.779 7,751 5,704 3,938 2,404 1,092